Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
14
0
0
11
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
21.4%
3 terminated out of 14 trials
78.6%
-7.9% vs benchmark
0%
0 trials in Phase 3/4
55%
6 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (14)
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Arsenic Trioxide in Treating Patients With Urothelial Cancer
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer